NDAQ
56
3
ROK
42
4
APH
65
4
DD
64
9
COF
60
3
AMAT
46
6
NSC
53
6
AVGO
32
7
PFE
21
-2
RIG
58
3
ROP
53
2
NI
63
3
FOXA
63
3
EQT
30
5
IR
61
6
ETN
69
2
MDLZ
38
2
MSI
63
2
UNH
55
5
GIS
29
3
NDAQ
56
3
ROK
42
4
APH
65
4
DD
64
9
COF
60
3
AMAT
46
6
NSC
53
6
AVGO
32
7
PFE
21
-2
RIG
58
3
ROP
53
2
NI
63
3
FOXA
63
3
EQT
30
5
IR
61
6
ETN
69
2
MDLZ
38
2
MSI
63
2
UNH
55
5
GIS
29
3
Financhill
Back

Editas Medicine 10K Form

Sell
49

EDIT
Editas Medicine

Last Price:
3.28
Seasonality Move:
21.39%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EDIT News And Ratings

See the #1 stock for the next 7 days that we like better than EDIT

EDIT Financial Statistics

Sales & Book Value

Annual Sales: $78.12M
Cash Flow: $-55.51M
Price / Cash Flow: 0
Annual Sales: $2.13
Price / Book: 1.47

Profitability

EPS (TTM): -2.56000
Net Income (TTM): $-210.57M
Gross Margin: --
Return on Equity: -74.59%
Return on Assets: -48.82%

Editas Medicine Earnings Forecast

Key Editas Medicine Financial Ratios

  • The Research & Development expenses have been 227.40% of Revenue.
  • The Interest Expense is 5.47% of Operating Income.
  • The Net Earning history of EDIT is -196.13% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 4 years.

Editas Medicine Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: EDIT
CUSIP: 28106W
Website: editasmedicine.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.75
Quick Ratio: 3.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EDIT Technical Analysis vs Fundamental Analysis

Sell
49
Editas Medicine (EDIT) is a Sell

Is Editas Medicine a Buy or a Sell?

  • Editas Medicine stock is rated a Sell
    The current Editas Medicine [EDIT] share price is $3.12. The Score for EDIT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.